Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProTrans for severe viral pneumonia
NCT04896853Phase 1Active, not recruiting
- Sponsor
- NextCell Pharma AB
- Start
- May 2021
- Primary completion
- Mar 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ProTrans in viral pneumonia and acute respiratory distress syndrome (ARDS), sponsored by NextCell Pharma AB. Primary endpoint: Safety and tolerance of a single infusion of ProTrans® at 24 months. Started May 2021; status: active, not recruiting.
02
Drugs
ProTrans
03
Conditions
viral pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04896853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896853.